

less need for injected insulin,” said **Esther Latres, JDRF Director, Translational Development**, “To achieve that goal would be one incredible step toward improving the quality of life for people with T1D while we strive for our ultimate goal of a cure.”

Dr Narendra Chirmule, Sr. Vice President & Head of R&D at Biocon, added, “We are thankful to JDRF for extending their support to our R&D efforts that are aimed at developing a novel oral insulin to treat type 1 diabetes. The primary objective of this study will be to evaluate the safety and tolerability of multiple ascending doses of Insulin Tregopil in individuals with type 1 diabetes. We are excited to work on this novel molecule and to partner with the world's leading organization supporting T1D research, JDRF.”

Globally, an estimated 422 million adults were living with diabetes in 2014. While separate global estimates of diabetes prevalence for type 1 and type 2 do not exist, it is estimated that 1.25 million Americans are living with T1D. Five million people in the U.S. are expected to have T1D by 2050.

Biocon had announced positive clinical data in 2016 for Insulin Tregopil following a set of Phase I studies conducted in the U.S., which established the drug's important role in postprandial glycaemic control. One of the studies demonstrated fast action of Insulin Tregopil with distinctive properties compared to other prandial insulins. Based on the positive data sets, Biocon has decided to advance this research asset through clinical trials for validation in a larger patient cohort. The company has also filed a Clinical Trial Application with the Indian regulator (DCGI) for a Phase II/III study with Insulin Tregopil in type 2 diabetes.